General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima))
Last updated May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima)
Last updated May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with imatinib, sunitinib, and regorafenib
Last updated May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Last updated May 11, 2023
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation (in combination with pembrolizumab)
Last updated May 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC), in adult patients (In combination with pembrolizumab)
Last updated May 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Acute Graft-Versus-Host disease
Last updated May 5, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Graft-versus-host Disease
Last updated May 5, 2023
Wakix (pitolisant hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Paladin Labs Inc.
Indication:
Excessive daytime sleepiness or cataplexy in adult patients with narcolepsy
Last updated May 3, 2023
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Diabetic Macular Edema
Last updated April 27, 2023